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Background: The aim of this discovery study was the identification of peptide serum biomarkers for detecting
biliary tract cancer (BTC) using samples from healthy volunteers and benign cases of biliary disease as control
groups. This work was based on the hypothesis that cancer-specific exopeptidases exist and that their activities in
serum can generate cancer-predictive peptide fragments from circulating proteins during coagulation.
Methods: This case control study used a semi-automated platform incorporating polypeptide extraction linked to
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) to profile 92 patient
serum samples. Predictive models were generated to test a validation serum set from BTC cases and healthy volunteers.
Results: Several peptide peaks were found that could significantly differentiate BTC patients from healthy controls and
benign biliary disease. A predictive model resulted in a sensitivity of 100% and a specificity of 93.8% in detecting BTC in
the validation set, whilst another model gave a sensitivity of 79.5% and a specificity of 83.9% in discriminating BTC from
benign biliary disease samples in the training set. Discriminatory peaks were identified by tandem MS as fragments of
abundant clotting proteins.
Conclusions: Serum MALDI MS peptide signatures can accurately discriminate patients with BTC from healthy volunteers.
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Cholangiocarcinoma (CCA) is a tumour which arises
from biliary epithelium within the liver (intrahepatic
CCA) or from the extrahepatic bile ducts (extrahepatic
CCA). Gallbladder carcinomas together with CCA are
often grouped as biliary tract cancer (BTC) [1]. CCA is
the second most common liver tumour, accounting for
about 10% of primary liver malignancies although the in-
cidence is rising [2,3]. Primary sclerosing cholangitis
(PSC) can cause benign biliary stricturing and is the
most common risk factor for CCA in Western popula-
tions, with rates of 8-30% reported in clinical follow-up* Correspondence: stephen.pereira@ucl.ac.uk
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distribution, and reproduction in any mediumor liver explant specimens after transplant. The prognosis
of CCA is poor with an overall median reported survival
of less than 1 year after diagnosis [4]. Surgery is the only
curative treatment option at this time, with resectability
rates ranging from 36% to 77% [5,6]. Serum carbohydrate
antigen (CA19-9) has been extensively studied and is the
most common tumour marker used in assisting in the
diagnosis and monitoring of CCA [7]. However, CA19-9
can also be raised in benign biliary obstruction and chol-
angitis as well as other gastrointestinal and gynaecological
neoplasms [8], and is virtually undetectable in the 7% of
the population who are negative for the Lewis antigen [9].
More accurate circulating biomarkers in this aggressive
and fatal cancer are clearly needed.
In recent years, proteomic profiling strategies using
automated magnetic reverse-phase beads for analyte
capture and matrix-assisted laser desorption/ionisation
time-of-flight (MALDI-TOF) MS have reported apparententral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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creatic and gastric cancers [10-13]. Further work to iden-
tify the serum peptides suggest that they are mostly
fragments derived from endogenous proteins of high abun-
dance that may originate from protein breakdown products
of the clotting cascade formed ex vivo by cancer-specific
exoproteases [13].
The aim of this discovery study was to profile peptides
in serum collected from patients with BTC, patients with
benign biliary disease and healthy volunteers using mag-
netic C18 bead-based, solid-phase polypeptide extraction
followed by MALDI-TOF MS profiling. Predictive models
based on differential peptide peaks generated from a train-
ing set were tested on an independent validation set of
samples and a subset of the discriminant peptides were
identified by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS).
Methods
Patients and serum samples
This study was approved by the Joint UCL/UCLH Com-
mittees on the Ethics of Human Research (Committee A)
(Reference No. 06/Q0152/106). Sample collection followed
institutional Ethical Committee guidelines in accordance
with the principles outlined in the Declaration of Helsinki
and patient informed consent was obtained. Serum sam-
ples were prospectively collected from 92 patients diag-
nosed with BTC and benign biliary strictures or healthy
volunteers attending University College London Hospital
between 2006 and 2008. The BTC and benign patients
were a heterogeneous mix of patients none of whom were
receiving active chemotherapy or antibiotics for cholangitis
at the time of sampling. Healthy volunteers had no active
illnesses and were not on medication and were comprised
of relatives who accompanied the BTC and benign patients
to the clinic. A further set of 30 BTC and healthy volunteer
samples were also prospectively collected in 2009/2010 as
an independent validation set. Blood samples were collected
in 8.5 mL BD Vacutainer® SST™ Advance Tubes (Becton
Dickinson Diagnostics, New Jersey), gently inverted 5 times
and clotted at room temperature for 60 min. Samples were
then centrifuged at 2,200 rpm at 4°C for 12 min and serum
supernatant aliquoted into cryovials and frozen at -80°C
until further use. This standard operating procedure (SOP)
was used for all samples with those from healthy volunteers
processed at the same time as their relatives’ case samples.
Patients with BTC were histologically and/or cytologically
proven to have adenocarcinoma and were staged according
to the tumour-node-metastasis (TNM) system for either
CCA or gallbladder carcinoma [14]. Patients with benign
biliary disease had a range of diagnoses including PSC,
autoimmune pancreatitis/IgG4-associated cholangitis (AIP/
IAC), papillary stenosis/fibrosis, chronic pancreatitis and
sphincter of Oddi dysfunction. Serum liver biochemistry,C-reactive protein (CRP) and serum CA19-9 assays (elec-
tro-chemiluminescence immunoassay; Roche Modular)
were performed for all patients with malignant and be-
nign biliary disease. A CA19-9 value of >37 IU/mL was
considered as abnormal, as reported in several other studies
[7]. Tables 1 and 2 outline the clinical, demographic and
biochemical characteristics of the patients used in the dis-
covery phase of this study.
Polypeptide extraction and sample preparation
One aliquot of serum per subject was thawed and 3 × 50 μL
randomly distributed into three replica 96-well plates. Plates
were again stored at -80°C prior to running on separate days.
Serum polypeptides were extracted, mixed with matrix and
spotted onto MALDI target plates using a semi-automated
C18-coated magnetic bead-based extraction and spotting
protocol [15] (described in detail in Additional file 1). The
triplicate extracts from each sample were spotted in quad-
ruplicate onto MALDI target plates to generate 12 spot-
ting replicates per subject sample. For each target plate,
four replicate samples of a quality control human
serum (Sigma-Aldrich, Dorset, UK; #S7023) were ex-
tracted and run alongside case control samples to monitor
inter-assay variation.
MALDI-TOF MS data acquisition and processing of
spectral data
Spectral profiles were acquired automatically using an
Ultraflex MALDI-TOF/TOF mass spectrometer (Bruker
Daltonics, Bremen, Germany) and data quality filtering ap-
plied essentially as described [15] (see Additional file 1 for
details). ClinProTools (CPT) version 2.2 (Bruker Daltonics)
was used to process spectral data. Average peak areas and
standard deviations for the normalised data were calculated
for each clinical group (BTC, benign and healthy) prior to
statistical analysis.
Statistical analysis and validation
A peak list containing all spectra classified into groups
comparing BTC with healthy controls, and BTC with be-
nign, was generated in CPTv2.2. The m/z values repre-
senting the peaks were filtered by first applying an
Anderson-Darling test to assess the distribution of peak
areas. Significance in the change in average peak area
was then assessed using either a Student t-test (Anderson-
Darling P > 0.05 = normal distribution) or Wilcoxon test
(Anderson-Darling P < 0.05 = non-normal distribution).
Calculations accounted for the consequences of multiple
testing by using the Benjamini-Hochberg P-value adjust-
ment. Receiver Operating Characteristic (ROC) curves
were generated to compare sensitivity and specificity of
discriminating peaks. Classification models were gene-
rated from a training set consisting of 75% of the BTC and
healthy samples using the model generation function of
Table 1 Demographics and biochemical profile of the patient cohort used for biomarker discovery
Clinical group
Variable BTC PSC IAC Benign other Healthy
Number 39 10 7 14 22
Female: male 15:24 3:7 0:7 9:5 7:15
Age (yrs) 69 (27–93) 48 (22–76) 64 (43–71) 53 (35–47) 60 (39–78)
Bilirubin (μmol/L) 40 (8–616) 17 (7–457) 12 (5–40) 8 (4–38) ND
CA19-9 (U/mL) 295 (1–145528) 17 (1–4119) 15 (1–52) ND ND
CA19-9 >37 U/mL 30/39 3/10 1/4 ND ND
CRP mg/L (N < 5) 44.4 (1–171) 9.9 (1–194.2) 8.6 (5–35.7) ND ND
ALP (U/L) 577 (138–1925) 195 (98–514) 229 (69–642) ND ND
IgG4 g/L (N < 1.3 g/L) ND ND 1.5 (0.49-2.57) ND ND
WCC (x109/L) 8.2 (3.3-14.8) 6.0 (4.3-15.0)* 7.6 (2.3-9.8) ND ND
Neutrophils (x109/L) 5.9 (2.3-12.0) 3.3 (2.8-13.4)* 4.1 (0.7-5.4) ND ND
BTC, biliary tract cancer; PSC, primary sclerosing cholangitis; IAC, IgG4-associated cholangitis. Benign other group comprises sphincter of Oddi dysfunction, stenosis
of the Ampulla of Vater and chronic pancreatitis. CA19-9, carbohydrate antigen 19–9; CRP, C-reactive protein; ALP, alkaline phosphatase; IgG4, immunoglobulin
G4; WCC, white cell count. Unless otherwise indicated, values indicate median (with range); ND, not determined; *WCC and neutrophil counts were available for
only 6 of the 11 PSC patients.
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Support Vector Machine (SVM) and Genetic Algorithms
were tested and 20% leave-out cross validation (LOCV)
was carried out to select the best models for testing on the
remaining 25% of samples. Classification performances
were then compared. Simple models with defined thresh-
olds were also generated using the discriminatory peaks.
For this, a subroutine was written in Matlab to check all
combinations of peaks using normalised peak areas orTable 2 Demographics, clinical and pathological
characteristics of biliary tract cancer patients













Distal bile duct 4
Stage:
T1 or T2 18
T3 or T4 21
Deaths 33/39 (85%)
Median survival and range (months) 8.4 (1.4-43.9)log-transformed peak areas with various degrees of power
between −2 and 2 for each peak. Model classification
performances were then compared.
A second set of serum samples was prospectively col-
lected from patients with BTC (n = 14) and healthy vo-
lunteers (n = 16) (Additional file 2: Table S1). Sample
collection, handling and profiling methodology were iden-
tical. The aim of this phase of the study was to validate the
models generated in the discovery phase by assessing sen-
sitivity, specificity, positive and negative predictive values.
Identification of MALDI-TOF peptides/peaks
Discriminatory peaks were selected for identification by
LC-MS/MS. Individual BTC and healthy control samples
were selected for pooling based on the highest areas for
these peaks. Pools (400 μL total volume) were extracted
manually with 40 μL of RPC18 Dynabeads (50 mg/mL)
per pool and using 56 μL of elution buffer (50% aceto-
nitrile/0.1% TFA). Eluates were split into two and dried in
a SpeedVac. One sample was resuspended in phosphate
buffered saline (PBS) and run on a 10-20% 1.0 mm Tricine
gel and stained with InstantBlue (Novexin). Gel bands
(n = 12) were cut below the 20 kDa marker, destained by
shaking at room temperature for 30 min in 200 μL of
50% methanol/10% acetic acid and then washed in 100
μL of 100% acetonitrile with shaking for 15 min. Poly-
peptides were then extracted in 200 μL of 50% formic
acid, 25% acetonitrile, 15% isopropanol by vigorous shak-
ing for 2 hrs at room temperature. The extract was recov-
ered, dried down and resuspended in 0.1% formic acid.
One fifth of this sample was analysed by MALDI-TOF MS
as described above, to verify the presence of peaks of
interest. The remainder of the sample was subjected to
ZipTip clean-up and analysed by LC-MS/MS. The other
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and analysed directly by LC-MS/MS. Details of the LC-
MS/MS analysis are provided in Additional file 1.
Results
Detection of MALDI-TOF peaks discriminating BTC and
healthy controls
Ninety two serum samples comprising patients with BTC
(n = 39), benign biliary disease (n = 31), and healthy con-
trols (n = 22) were subjected to C18 reversed-phase ex-
traction in triplicate and analysed by MALDI-TOF MS
profiling. Assay performance was assessed within and
across runs using a quality control serum sample proc-
essed and spotted multiple times with test samples. The
profiling method gave an inter-assay CV of 12.8% +/− 6.7
using all detected peaks. For the discovery samples, 303
aligned peaks were detected in the m/z range 700–10,000
(Figure 1). Using a conservative P value cut-off of <0.001
and an average-fold change of ≥2.0, eight peaks discrimi-
nated the BTC and healthy groups (Table 3 and Additional
file 2: Table S2). Peaks m/z 887.2, 2903.3 and 5805.0 were
up-regulated in BTC samples, whereas peaks m/z 1263.7,
1350.8, 2082.1, 2210.3 and 2554.5 were down-regulated.
Box-and-whisker plots for these and an additional peak of
interest (m/z 2932.9; P = 0.002) are illustrated in Figure 2.
As examples, peaks m/z 5805.0 and m/z 2210.3
are shown in spectral and gel views in Figure 3. Two-
dimensional scatter plots of discriminatory peaks
showed the separation of BTC and healthy samples
(Additional file 2: Figure S1). In the comparison of the
BTC and benign cases, there were fewer discriminatory
peaks with seven showing a >1.5-fold change in area with
P < 0.05 (Additional file 2: Table S3). Six of these peaks
were common to both comparisons (m/z 887.2, 2082.1,
2210.3, 2554.5, 2903.3 and 5805.0) and displayed the same
directionality of change when comparing BTC with
healthy and benign (Figure 2). When BTC samples were
compared to the benign subset from ten PSC patients,
there were no significantly differentiating peaks detected.
Based on the quantitative data of the discovery set for
discriminating BTC from healthy volunteers, the area under
the ROC curves (AUROC) for peaks m/z 2903.3 5805.0,
2210.3 and 1263.7 were 0.97, 0.96, 0.92 and 0.91, respec-
tively (see Table 3 and Additional file 2: Figure S2, for ex-
ample ROC curves). For BTC versus benign cases, AUROC
values for the seven discriminatory peaks were in the range
0.73 to 0.78 (Additional file 2: Table S3).
Class prediction model generation and external validation
Seventy five per cent of the BTC and healthy control
samples were randomly assigned to a training set and
the remaining 25% assigned to a test set. Five permuta-
tions of these training and test sets were created. Class
prediction analysis was then performed using either theQuickClassifier, Supervised Neural Network, Genetic Al-
gorithms or Support Vector Machine (SVM) modelling
in the ClinProTools software with cross-validation using
20%-LOCV (10 iterations). Different models were tested
using various numbers of k-Nearest Neighbours (k-NN)
and peaks. Four hundred models were generated in total
for the five permutated sets. The best performing models
from this internal validation are shown in Additional file 2:
Table S4. The best was a 9 peak SVM (3 k-NN) model
which gave 94.4% accuracy on cross-validation and 100%
sensitivity, specificity, accuracy, positive predictive value
and negative predictive value for test set prediction. The
peaks automatically chosen by this model were m/z
1020.2, 1263.7, 1350.8, 1363.4, 2210.3, 2554.5, 2624.5,
2903.3, and 5064.8, and thus included five of the most dis-
criminatory peaks found in the discovery analysis (Table 3).
This model was next tested on profiling data from a sec-
ond independent set of BTC and healthy volunteer serum
samples. The sensitivity, specificity, positive and negative
predictive value (PPV, NPV) for the model were 92.9%,
100%, 100%, and 94.1%, respectively, and thus discrimi-
nated BTC from healthy samples with high accuracy. This
model however performed less well when tested for the
discrimination of BTC and benign cases.
Since there was no control over the peaks entering the
SVM and no thresholds defined, we sought to generate
and test simpler models using only the most discrimin-
atory peaks and to define usable thresholds. Peak m/z
2903.3 was excluded from this analysis as it was sus-
pected to be a doubly charged form of m/z 5805.0 and
therefore not an independent molecular species (see below).
The best model at discriminating the discovery BTC cases
from healthy controls was (5805)/(1350*2210*2554)*1000 >
0.3 (using normalised areas for each peak) with a sensitivity
of 97.4% and specificity of 100%. When tested on the in-
dependent validation set this model gave a sensitivity,
specificity, PPV and NPV of 100%, 93.8%, 92.9%, and
100% respectively, for discriminating BTC versus healthy
with an AUROC of 0.995 (95% CI 0.98-1.01), SE = 0.008
and P < 0.0001.
For predicting BTC versus benign cases, the best model
(((10*log878)*log1350*log5805^1.25)/(log2210^(1.5)*log255
4^(0.75)) > 5) gave a sensitivity, specificity, PPV and NPV of
79.5%, 83.9%, 86.1% and 76.5%, respectively, on the training
set data, although could not be tested independently due to
a lack of available samples from additional benign cases.
The most accurate model in discriminating BTC from both
healthy and benign controls was (5805)/(2082*2554*2923)
*1000 > 0.4, and provided a 92.3% sensitivity and 100% spe-
cificity for BTC versus healthy (AUROC= 0.981 (95% CI
0.95-1.01), SE = 0.014, P < 0.0001) and 92.3% sensitivity and
74.2% specificity for BTC versus benign (AUROC= 0.815





Figure 1 MALDI MS profiling of serum peptides in biliary disease. A. Average MALDI-TOF spectra for BTC (red) and healthy (green) serum
samples over the full scan range of m/z 700–10,000. B. Zoomed spectra over the m/z 1,700 to 6,900 range.
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Table 3 Significant peptide peaks differentiating BTC from healthy volunteers
Mass
(m/z)
Peak area Peak area Fold- change Wilcoxon test AUROC†
BTC +/− SD H +/− SD (BTC vs H) P value
887.2 5.2+/−7.1 1.8+/−0.5 2.82 0.000691 0.79
1263.7 21.8+/−9.9 47.4+/−22.7 0.46 <0.000001 0.91
1350.8 48.3+/−25.7 117.4+/−62.3 0.41 <0.000001 0.92
2082.1 10.0+/−3.4 24.4+/−20.5 0.41 0.0000364 0.86
2210.3 10.9+/−3.8 38.2+/−31.6 0.29 <0.000001 0.92
2554.5 24.8+/−17.8 57.3+/−20.6 0.43 <0.000001 0.91
2903.3 24.1+/−10.0 11.5+/−2.5 2.09 <0.000001 0.97
5805.0 33.0+/−30.9 6.7+/−1.6 4.93 <0.000001 0.96
*Wilcoxon test P values were corrected for multiple testing using the Benjamini-Hochberg adjustment. †Area under the Receiver Operating Characteristic curve.
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Discriminatory peaks used in the models were targeted for
identification by LC-MS/MS following C18 extraction and
separation on high-percentage 1D gels (Additional file 2:
Figure S3). Four of 13 peaks of interest were identified,
three of which have been reported in other studies, adding
confidence to the identifications (Figure 4 and Additional
file 2: Table S5). The identities of five more peaks were in-
ferred from previous studies [13,16] including our own
[17], whilst the remaining peaks eluded identification.
Most of the identified and predicted peptides are derived
from fibrinogen alpha, with a peptide also identified from
the abundant serum protein kininogen. These peptidesFigure 2 Peaks discriminatory for BTC versus benign biliary disease and
are shown for differential peptide peaks for biliary tract cancer BTC; dark grey)are hypothesized to be generated through the actions of
blood-borne clotting endopeptidases and as yet uncharac-
terised exopeptidases [13].
Discussion
In this study we identify serum peptide peaks as potential
markers of BTC utilising a high-throughput C18 bead-
based extraction method linked to MALDI-TOF MS pro-
filing and LC-MS/MS for subsequent peak identification.
A predictive model using an SVM consisting of nine peaks
was able to distinguish BTC from healthy controls in a
set of independent validation samples with a high de-
gree of accuracy. Several of these same peptides couldhealthy controls. Box-and-whisker plots of peak area (5–95 percentile)

















Figure 3 Average spectra, gel and 3D spectral views for two significant peaks discriminating BTC (red) and healthy control (green)
samples. A. The peak at m/z 2212.3 was generally of lower intensity in BTC samples compared to healthy samples. B. The peak at m/z 5805.0
was generally of higher intensity in BTC samples compared to healthy samples.
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ease albeit with lower accuracy, though none were dis-
criminatory when using a smaller subset of 10 samples
from patients diagnosed with PSC.
Serum profiling using proteomics has developed signifi-
cantly from its early years when it was claimed that
surface-enhanced laser desorption ionisation time-of-flight
mass spectrometry (SELDI-TOF MS) profiling could reveal
discriminatory peaks of high diagnostic accuracy for various
cancers [18-22]. Following the initial excitement, scepticism
about the methodology mounted with reports of experi-
mental bias within datasets and evidence that variations in
sample handling gives rise to “differential” peptides previ-
ously reported as cancer markers [23-27]. Our study was
designed prior to sample collection, and hence all samplesunderwent the same process of prospective collection and
were handled using a robust SOP. These aspects are crucial
to avoid variability in profiling particularly as the peptides
of interest are thought to be generated from products of
the clotting cascade ex vivo.
Our main aim was to identify low molecular weight
polypeptides in serum for detecting BTC using healthy
volunteers and benign cases of biliary disease as control
groups. This work was based on the hypothesis that
cancer-specific exoproteases in serum act to digest prod-
ucts of the clotting cascade ex vivo, generating peptide
fragments which may discriminate cancer from healthy
samples [13,28,29]. As such, serum, rather than plasma
was chosen for this study. Analysis of spectral profiles from
92 serum samples gave eight significant peaks (P < 0.001)
AB
Figure 4 MS/MS fragmentation and sequence data for identified peptides. A. The m/z 5805.0 peak (SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEAD
HEG-THSTKRGHAKSRP) was identified as a fragment of isoform 1 of fibrinogen alpha chain (IPI00021885) with an ion score of 122 from m/z [726.214]8+.
The spectrum shown is the sum of 28 scans in range 130 (rt = 22.952) to 198 (rt = 31.9511). B. The m/z 1350.8 peak (SGEGDFLAEGGGVR) was also identified
as a fragment of fibrinogen alpha chain with an ion score of 95 from m/z [675.82]2+.
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and healthy subjects. Two of these peaks (m/z 5805.0 and
m/z 2903.3) had higher peak areas in BTC versus healthy,
whilst the other six peaks were higher in the healthy sam-
ples. The best model generated from the discovery data
using several of these peaks gave 100% sensitivity, 93.8%
specificity, 92.9% PPV and 100% NPV when tested on the
independent validation dataset, showing the potential of
the test for accurate diagnosis of BTC.
Biliary strictures can arise from several non-malignant
conditions which can mimic BTC, such as AIP/IAC, PSC
and chronic pancreatitis. There were seven significant
(and overlapping) peaks discriminating samples from pa-
tients with BTC versus benign biliary disease and a modelwas generated from the discovery data with respectable
diagnostic accuracy (79.5% sensitivity, 83.9% specificity),
These peaks, particularly m/z 5805.0, may therefore be of
utility in differentiating BTC from benign disease. Despite
this, the profiling failed to accurately differentiate patients
with BTC versus the small subset of patients with PSC – a
risk factor for BTC [30]. This may be due to the low num-
ber of samples used or the fact that the identified peaks
may be markers of inflammation of the biliary epithelium.
Indeed, the median level of C-reactive-protein (CRP) was
significantly higher in the BTC patients than in the PSC
cohort (Table 1). Whilst our preliminary findings would
argue against this, further independent validation using
greater numbers of samples from patients with PSC and
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the robustness of this model for the differential diagnosis
of BTC. It is noteworthy that other cancer biomarker dis-
covery studies using similar methodologies have not in-
cluded benign inflammatory groups [13,31] and it is now
becoming evident that this is absolutely critical. One re-
cent study in pancreatobiliary disease has addressed this
issue, with the study identifying a potential marker of
malignancy in bile (NGAL) that was independent of
markers of biliary obstruction and inflammation [32].
As in the present study, further validation of this marker
is required.
An ion of mass [726.214]8+ was identified as the 576–
628 fragment of isoform 1 of fibrinogen alpha chain by
LC-MS/MS with a calculated average mass of 5805.09 Da
and we matched this to the MALDI-TOF peak at m/z
5805.0. This peak may be generated by the exopeptidase-
mediated loss of valine from the abundant peak at m/z
5903.9, which has been identified as a large fragment of fi-
brinogen alpha [17]. It may thus represent a surrogate
marker of a tumour-derived exoprotease that is present at
higher levels in the blood of BTC patients. The lower in-
tensity peak at m/z 2903.3 behaved similarly to m/z
5805.0, but could not be identified. Its mass, isotopic pat-
tern and expression behaviour suggest it to be a doubly-
charged form of m/z 5805.0. As such, both peaks cannot
be used as independent discriminating features, although
we note that only the peak at m/z 2903.3 was selected by
the SVM model used for validation. The other discrimin-
atory peaks were also identified as fragments of fibrinogen
alpha/fibrinopeptide A and high molecular weight kinino-
gen, which have been reported as surrogate markers of
different cancer types [13].
Exoproteases form a heterogeneous group of enzymes
that play a role in the regulation of biologically active
peptides. Examples such as leucine aminopeptidase, ami-
nopeptidase A, aminopeptidase N, carboxypeptidase N
and the kininase I family of carboxypeptidases are in-
volved in the production of angiotensin, bradykinin and
vasopressin [33], whilst carboxypeptidase B2 is involved
in the down-regulation of fibrinolysis [34]. Through such
activities, they may also contribute to tumour progres-
sion and invasiveness. In particular, several studies have
reported the elevated expression of aminopeptidase N/
CD13 in various cancers [35-38] and it is believed to
play a role in angiogenesis [39]. We speculate that the
peptide fragments detected in our study are likely to be
generated by such exopeptidase activities and thus serve
as surrogate markers of the exoproteases themselves.
The identity of these proteases was not the focus of this
study, but their future interrogation in BTC may shed
further light on its pathophysiology and lead to the iden-
tification of tumour-specific biomarkers and possible
targets for therapy.Various fibrinogen alpha chain and fibrinopeptide A
fragments have been detected in hepatocellular, ovarian,
urothelial and gastric cancers [13,40-43], although the
m/z 5805.0 fragment has not been identified previously.
These cleavage products may therefore be indicative of
an underlying malignancy rather than be specific for
BTC. However, we do note that our group could not derive
a peptide signature to accurately differentiate ovarian can-
cer from benign ovarian disease or healthy controls using
serum peptides detected on the same profiling platform
[15]. This suggests that the signature identified herein,
displays some specificity for BTC.
There are several limitations to the present study. The
SOP adopted for this study used a clotting time of 60
minutes and therefore may be difficult to translate into
the clinical laboratory where time and staff limitations
are restrictive. In addition, the extraction and MALDI-TOF
MS profiling method used here requires considerable ex-
pertise for operation and determines only relative peptide
quantities. Given the nature of the peptides, the generation
of fragment-specific antibodies for use in immune-based as-
says may be problematic and so MS-based targeted assays
using synthetic, stable isotope-labelled peptide standards
for accurate quantitation would be a more attractive way to
validate our findings. Finally, the validation would require
larger sample numbers, particularly those from cases of be-
nign biliary disease.Conclusions
In conclusion we have defined a serum peptide signature
and model than can accurately discriminate patients with
BTC from healthy volunteers and which was validated on
an independent sample set. A model using an overlapping
set of peptides was also derived that could differentiate
malignant from benign disease, albeit with a lower, but re-
spectable, accuracy. Further independent validation of this
model is now required using greater numbers of samples
from patients with PSC and other benign conditions to
test its robustness for the differential diagnosis of BTC.Additional files
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